STOCK TITAN

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
management

Atossa Therapeutics (Nasdaq: ATOS) has appointed Claudia Lopez, DVM, MSc, as Vice President of Clinical Product Development. Dr. Lopez brings over 20 years of clinical development and strategic expertise, particularly in immunology, oncology, and metabolic disease. Previously Vice President of Clinical Development at Landos Biopharma, she has held leadership positions at Arena Pharmaceuticals and Takeda Pharmaceuticals. In her new role, Dr. Lopez will focus on advancing Atossa's clinical pipeline for breast cancer treatments, leveraging her experience in global clinical strategies, trial design, and regulatory alignment.

Atossa Therapeutics (Nasdaq: ATOS) ha nominato Claudia Lopez, DVM, MSc, come Vicepresidente dello sviluppo prodotto clinico. La Dr.ssa Lopez porta con sé oltre 20 anni di esperienza nello sviluppo clinico e nella strategia, particolarmente in immunologia, oncologia e malattie metaboliche. In precedenza Vicepresidente dello sviluppo clinico presso Landos Biopharma, ha ricoperto ruoli di leadership in Arena Pharmaceuticals e Takeda Pharmaceuticals. Nel suo nuovo ruolo, la Dr.ssa Lopez si concentrerà sull'avanzamento del pipeline clinico di Atossa per i trattamenti del cancro al seno, sfruttando la sua esperienza nelle strategie cliniche globali, nella progettazione degli studi e nell'allineamento normativo.

Atossa Therapeutics (Nasdaq: ATOS) ha nombrado a Claudia Lopez, DVM, MSc, como Vicepresidenta de Desarrollo de Productos Clínicos. La Dra. Lopez aporta más de 20 años de experiencia en desarrollo clínico y estrategia, especialmente en inmunología, oncología y enfermedades metabólicas. Anteriormente fue Vicepresidenta de Desarrollo Clínico en Landos Biopharma, y ha ocupado cargos de liderazgo en Arena Pharmaceuticals y Takeda Pharmaceuticals. En su nuevo puesto, la Dra. Lopez se enfocará en avanzar en la cartera clínica de Atossa para tratamientos del cáncer de mama, aprovechando su experiencia en estrategias clínicas globales, diseño de ensayos y alineación regulatoria.

Atossa Therapeutics (Nasdaq: ATOS)는 Claudia Lopez, DVM, MSc를 임상 제품 개발 부사장으로 임명했습니다. Lopez 박사는 면역학, 종양학 및 대사 질환 분야에서 20년 이상의 임상 개발 및 전략적 전문 지식을 보유하고 있습니다. 그녀는 이전에 Landos Biopharma의 임상 개발 부사장이었으며, Arena Pharmaceuticals 및 Takeda Pharmaceuticals에서 리더십 직책을 역임했습니다. 새로운 역할에서 Lopez 박사는 Atossa의 유방암 치료 임상 파이프라인을 발전시키는 데 집중하며, 글로벌 임상 전략, 시험 설계 및 규제 조정에 대한 경험을 활용할 것입니다.

Atossa Therapeutics (Nasdaq: ATOS) a nommé Claudia Lopez, DVM, MSc au poste de Vice-Présidente du Développement de Produits Cliniques. La Dr. Lopez apporte plus de 20 ans d'expertise en développement clinique et en stratégie, notamment en immunologie, oncologie et maladies métaboliques. Ancienne Vice-Présidente du Développement Clinique chez Landos Biopharma, elle a occupé des postes de direction chez Arena Pharmaceuticals et Takeda Pharmaceuticals. Dans son nouveau rôle, la Dr. Lopez se concentrera sur l'avancement de la pipeline clinique d'Atossa pour les traitements du cancer du sein, tirant parti de son expérience en stratégies cliniques mondiales, en conception d'essais et en alignement réglementaire.

Atossa Therapeutics (Nasdaq: ATOS) hat Claudia Lopez, DVM, MSc zur Vizepräsidentin für klinische Produktentwicklung ernannt. Dr. Lopez bringt über 20 Jahre Erfahrung in der klinischen Entwicklung und strategischen Expertise mit, insbesondere in den Bereichen Immunologie, Onkologie und Stoffwechselerkrankungen. Zuvor war sie Vizepräsidentin für klinische Entwicklung bei Landos Biopharma und hatte Führungspositionen bei Arena Pharmaceuticals und Takeda Pharmaceuticals inne. In ihrer neuen Rolle wird Dr. Lopez sich darauf konzentrieren, die klinische Pipeline von Atossa für die Behandlung von Brustkrebs voranzutreiben, indem sie ihre Erfahrungen in globalen klinischen Strategien, Versuchsdesign und regulatorischer Abstimmung nutzt.

Positive
  • Appointment of experienced executive with 20+ years in clinical development
  • Strategic expertise in global clinical programs and regulatory processes
  • Strong background in oncology and clinical trial management
Negative
  • None.

Dr. Lopez Brings 20+ Years of Global Clinical Development and Leadership to Support Atossa’s Mission in Developing Innovative Breast Cancer Therapies

SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced the appointment of Claudia Lopez, DVM, MSc, as its new Vice President, Clinical Product Development. Dr. Lopez brings more than two decades of clinical development and strategic expertise to Atossa, including leadership roles in global clinical programs across immunology, oncology, and metabolic disease. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer.

Dr. Lopez most recently served as Vice President of Clinical Development at Landos Biopharma, where she oversaw global clinical strategies, trial design, and regulatory alignment. Her leadership has consistently driven successful clinical programs from early-stage development through complex global regulatory processes. In her new role at Atossa, Dr. Lopez will focus on advancing Atossa’s clinical pipeline, contributing to the development and delivery of next-generation cancer treatments.

“We are pleased to welcome Dr. Lopez to the Atossa team. Her extensive experience in clinical development, particularly her strategic acumen in guiding multifaceted clinical trials, aligns perfectly with our mission to bring transformative treatments to women with breast cancer,” said Dr. Steven Quay, Chief Executive Officer of Atossa Therapeutics. “Claudia’s leadership will be instrumental in driving Atossa’s clinical programs forward as we work to improve outcomes for breast cancer patients across the treatment continuum.”

Dr. Lopez has built an impressive career spanning leadership roles at Landos Biopharma, Arena Pharmaceuticals, and Takeda Pharmaceuticals, where she held key positions in clinical development allowing her to successfully lead global programs. She has directed cross-functional teams, led regulatory submissions in the U.S. and Europe, and managed comprehensive clinical development programs in areas such as inflammatory bowel disease, diabetes, melanoma, and breast cancer. Her expertise in aligning clinical strategy with regulatory and commercial goals will be invaluable to Atossa’s growth.

“I am honored to join Atossa at this exciting stage,” said Dr. Lopez. “The potential of Atossa’s pipeline in breast cancer is compelling, and I look forward to contributing my experience to advance these promising therapies.”

About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.

Contact
Michael Parks, VP Investor and Public Relations
484-356-7105
michael.parks@atossainc.com

FORWARD LOOKING STATEMENTS
This press release contains certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as “expect,” “potential,” “continue,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate,” “believe,” “future,” or other comparable words. Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes, such as data related to the (Z)-endoxifen program, the potential of (Z)-endoxifen as a breast cancer prevention and treatment agent, and potential milestones and growth opportunities for the Company, to differ materially from those projected or anticipated, including risks and uncertainties associated with: macroeconomic conditions and increasing geopolitical instability; the expected timing of releasing data; any variation between interim and final clinical results; actions and inactions by the FDA and foreign regulatory bodies; the outcome or timing of regulatory approvals needed by Atossa, including those needed to continue our planned (Z)-endoxifen trials; our ability to satisfy regulatory requirements; our ability to remain compliant with the continued listing requirements of the Nasdaq Stock Market; our ability to successfully develop and commercialize new therapeutics; the success, costs and timing of our development activities, including our ability to successfully initiate or complete our clinical trials, including our (Z)-endoxifen trials; our anticipated rate of patient enrollment; our ability to contract with third-parties and their ability to perform adequately; our estimates on the size and characteristics of our potential markets; our ability to successfully defend litigation and other similar complaints and to establish and maintain intellectual property rights covering our products; whether we can successfully complete our clinical trial of oral (Z)-endoxifen in women with mammographic breast density and our trials of (Z)-endoxifen in women with breast cancer, and whether the studies will meet their objectives; our expectations as to future financial performance, expense levels and capital sources, including our ability to raise capital; our ability to attract and retain key personnel; our anticipated working capital needs and expectations around the sufficiency of our cash reserves; and other risks and uncertainties detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its Annual Reports on Form 10-K and Quarterly Reports on 10-Q. Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.


FAQ

Who did Atossa Therapeutics (ATOS) appoint as VP of Clinical Product Development?

Atossa Therapeutics appointed Dr. Claudia Lopez, DVM, MSc, as Vice President of Clinical Product Development.

What is Dr. Claudia Lopez's previous experience before joining ATOS?

Dr. Lopez previously served as Vice President of Clinical Development at Landos Biopharma and held leadership positions at Arena Pharmaceuticals and Takeda Pharmaceuticals, with over 20 years of experience in clinical development.

What will be Dr. Lopez's main responsibilities at Atossa Therapeutics (ATOS)?

Dr. Lopez will focus on advancing Atossa's clinical pipeline, contributing to the development and delivery of next-generation cancer treatments, particularly in breast cancer therapies.

Atossa Therapeutics, Inc.

NASDAQ:ATOS

ATOS Rankings

ATOS Latest News

ATOS Stock Data

179.83M
125.76M
0.06%
27.49%
10.38%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SEATTLE